Omrix shareholder Gabelli buys 1.28 million shares

By Lisa Kerner

Charlotte, N.C., Dec. 18 - Investors led by Gabelli Funds, LLC bought 1,276,283 shares of Omrix Biopharmaceuticals, Inc. for a 7.48% ownership interest in the company, it was reported in a schedule 13D filed with the Securities and Exchange Commission.

The shares were acquired between Oct. 23 and Nov. 24 at prices from $12.92 to $24.90 each, the filing said.

In November, New Brunswick, N.J.-based pharmaceutical company Johnson & Johnson began a $25.00-per-share cash tender offer to purchase all outstanding shares of Omrix's common stock.

The offer will expire at midnight ET on Dec. 23 unless extended, it was previously reported.

Omrix is a New York-based biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.